Welcome to DU! The truly grassroots left-of-center political community where regular people, not algorithms, drive the discussions and set the standards. Join the community: Create a free account Support DU (and get rid of ads!): Become a Star Member Latest Breaking News General Discussion The DU Lounge All Forums Issue Forums Culture Forums Alliance Forums Region Forums Support Forums Help & Search

marmar

(77,073 posts)
Sat Oct 3, 2015, 08:34 AM Oct 2015

Pfizer Raised Prices on 133 Drugs This Year, And It's Not Alone


(Bloomberg) A single, 5,000 percent price hike on an anti-parasitic drug made by Turing Pharmaceuticals garnered national media attention. But it’s just one of hundreds of smaller price increases drug companies make in the U.S. each year, a tactic the industry uses to generate more revenue from older medications.

Pfizer Inc., the nation’s biggest drugmaker, has raised prices on 133 of its brand-name products in the U.S. this year, according to research from UBS, more than three-quarters of which added up to hikes of 10 percent or more. It’s not alone. Rival Merck & Co. raised the price of 38 drugs, about a quarter of which resulted in increases of 10 percent or more. Pfizer sells more than 600 drugs globally while Merck has more than 200 worldwide, including almost 100 in the U.S.

Drugmakers have long said these increases aren’t felt by most consumers because intermediaries like insurers negotiate what is ultimately paid -- meaning what they really charge for their drugs is far below the list price. Pfizer and its rivals say they can’t make those negotiated prices public for competitive reasons.

Like its competitors, Pfizer has been raising prices on older drugs in its portfolio for years. The increases in the U.S. have added $1.07 billion of quarterly revenue from mid-2012 to the middle of this year, helping limit the company’s total decline in quarterly revenue over that time period to $2 billion even as patents on blockbuster drugs expired, according to estimates from SSR, an investment research firm. In the case of Bristol-Myers Squibb Co., increasing the price of existing drugs in the U.S. brought in $435 million of revenue over the past three years, leaving the contraction of the company’s global sales at $280 million, SSR estimates show. .................(more)

http://www.bloomberg.com/news/articles/2015-10-02/pfizer-raised-prices-on-133-drugs-this-year-and-it-s-not-alone




7 replies = new reply since forum marked as read
Highlight: NoneDon't highlight anything 5 newestHighlight 5 most recent replies
 

Facility Inspector

(615 posts)
1. More people with government mandated for profit health insurance
Sat Oct 3, 2015, 09:25 AM
Oct 2015

means there is a greater pool of marks for allied industries to skim their take,

Shilling the rubes, baby, shilling the rubes.

FlatBaroque

(3,160 posts)
2. Pfizer and its rivals say they can’t make those negotiated prices public for competitive reasons.
Sat Oct 3, 2015, 09:26 AM
Oct 2015

This is corporatism and it is INSANE

Recursion

(56,582 posts)
5. "Drugmakers have long said these increases aren’t felt by most consumers...
Sat Oct 3, 2015, 11:42 AM
Oct 2015

...because intermediaries like insurers negotiate what is ultimately paid"

Aaaaaaand.... we see the problem.

ryan_cats

(2,061 posts)
7. I don't have too much of
Sat Oct 3, 2015, 11:44 AM
Oct 2015

I don't have too much of a problem with this.
If the drug company spent a billion dollars developing a drug, they certainly deserve to recoup that investment.

If they buy a drug from someone else that costs $2.00 to make, then not so much, especially if it's an ED drug as preventing those people from having it affects their very lives.

Latest Discussions»General Discussion»Pfizer Raised Prices on 1...